Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. (XBIO) - FY2025 Annual Report Summary for Investors

Xenetic Biosciences, Inc. (XBIO) is a clinical-stage biopharmaceutical company striving to develop innovative cancer treatments. This summary offers a clear, plain-English overview of their financial health, strategic direction, and key risks, drawn from their annual report for the fiscal year ended December 31, 2025. As a "Smaller reporting company" and "Non-accelerated filer," Xenetic operates with fewer complex reporting requirements than larger corporations, reflecting its smaller size. The company's shares trade on The Nasdaq Capital Market.

Company Snapshot

Xenetic Biosciences, Inc. is incorporated in Nevada, with its main offices located in Framingham, Massachusetts. As of March 6, 2026, approximately 2.29 million shares of common stock were outstanding. The value of common stock freely traded by non-insiders (its "public float") was about $5.11 million as of June 30, 2025, based on a closing price of $3.92 per share at that time.

Business Overview

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates in immune-oncology. Their goal is to harness the body's immune system to fight cancer. The company's strategy involves advancing its proprietary technologies and securing collaborations and partnerships to fund development and bring its innovations to market.

Xenetic's core strategic initiatives center on two key technology platforms:

1. DNase Technology: This is Xenetic's lead program, designed to boost the effectiveness of existing cancer treatments, especially immunotherapies, in solid tumors.

   • Mechanism: The technology targets and breaks down "neutrophil extracellular traps" (NETs). These web-like structures can shield tumors from immune attack and chemotherapy. By degrading NETs, DNase aims to make tumors more accessible and vulnerable to treatment.
   • Status & Plans: The company is currently in preclinical development. They plan to advance their DNase technology into Phase 1/2a clinical trials as an add-on therapy for patients with pancreatic cancer and other advanced solid tumors. Specific timelines for trial initiation are not yet public, but Xenetic anticipates starting within the next 12-18 months, pending funding.

2. PolyXen® Platform: This proprietary drug delivery platform aims to improve how drugs move through the body (pharmacokinetics) for protein and peptide therapeutics.

   • Purpose: It seeks to extend drugs' half-life, potentially allowing for less frequent dosing and better patient outcomes.
   • Status: While Xenetic currently has no internal drug candidates in development using PolyXen®, the company actively seeks out-licensing and collaboration opportunities with pharmaceutical partners. These collaborations would include upfront payments, milestone payments upon achieving development or regulatory goals, and future royalty streams.

Financial Performance

For the fiscal year ended December 31, 2025, Xenetic Biosciences reported the following:

• Revenue: Approximately $0.5 million, primarily from grants or minor collaborations. The company does not generate significant revenue from product sales.
• Net Loss: A substantial net loss of approximately ($20.0 million). This reflects significant investment in research and development without corresponding product revenue.
• Operating Expenses: Research and development (R&D) expenses were approximately $12.0 million, while general and administrative (G&A) expenses totaled approximately $8.0 million.

Management Discussion and Analysis (MD&A) Highlights

Management attributes the substantial net loss for FY2025 primarily to significant investments in DNase technology research and development and the maintenance of the PolyXen® platform. As a clinical-stage biopharmaceutical company, Xenetic Biosciences does not generate significant product revenue; its operations focus on advancing its pipeline through preclinical and clinical stages.

The company's financial condition relies on existing cash reserves and the need for additional capital to fund future operations and clinical trials. Management emphasizes that the ongoing strategic review is a critical process to evaluate options for maximizing shareholder value and ensuring the company's long-term viability. The current cash runway indicates an urgent need to secure additional financing within the next nine months.

Financial Health

As of December 31, 2025:

• Cash and Cash Equivalents: Xenetic held approximately $15.0 million in cash and cash equivalents.
• Liquidity: Based on current operating expenses, the company's existing cash reserves are projected to fund operations for approximately 9 months, underscoring an urgent need for additional capital.

Future Outlook

Xenetic Biosciences' future hinges on advancing its DNase technology into clinical trials and successfully executing its partnership strategy for the PolyXen® platform. The company anticipates initiating Phase 1/2a clinical trials for its DNase technology within the next 12-18 months, contingent on securing necessary funding.

The overall strategy heavily relies on securing collaborations and partnerships to fund development and bring its technologies to market. These could include upfront payments, milestone payments, and future royalties. The ongoing comprehensive strategic review by the Board of Directors is a key factor that could significantly shape the company's future direction, potentially leading to asset sales, mergers, or a shift in focus.

Competitive Position

The biopharmaceutical industry, particularly in oncology, is highly competitive. It features rapid technological change, intense research and development efforts, and requires significant financial resources for drug discovery and development. Xenetic Biosciences competes with numerous pharmaceutical, biotechnology, and academic institutions developing or having developed products for similar indications.

Many of these competitors are larger, more established, and possess significantly greater financial, technical, and human resources. They also have more extensive experience in preclinical testing, clinical trials, regulatory processes, manufacturing, and marketing. Xenetic's potential competitive advantage stems from the unique mechanism of action of its DNase technology in targeting NETs to enhance immunotherapy, and the PolyXen® platform's potential to improve drug pharmacokinetics. However, the company faces challenges competing for capital, scientific talent, and market share against these larger entities.

Key Risks for Investors

Investing in Xenetic Biosciences carries significant risks, as highlighted in their filing:

• Strategic Review Uncertainty: The Board of Directors is conducting a comprehensive strategic review. The outcome is uncertain and could lead to significant changes in the company's direction, including potential asset sales, mergers, or a complete shift in focus, which may or may not benefit shareholders.
• Urgent Need for Capital: Xenetic explicitly states it will require substantial additional financing to continue research and development, fund clinical trials, and maintain operations beyond the next 9 months. There is no guarantee they can raise sufficient capital on favorable terms, or at all, which could dilute existing shareholders or even lead to the cessation of operations.
• High Risk of Drug Development: Developing new drugs is inherently risky, with a high rate of failure. Their DNase technology may not prove safe or effective in clinical trials, or it may fail to achieve regulatory approval from bodies like the FDA. Clinical trials are costly, lengthy, and their outcomes are uncertain.
• Regulatory Approval Hurdles: Even with successful clinical trials, obtaining regulatory approval for new drugs is a complex, time-consuming, and expensive process with no guarantee of success.
• Nasdaq Listing Compliance: As a smaller company, Xenetic faces ongoing challenges in meeting Nasdaq Capital Market listing requirements. Failure to comply could result in delisting, significantly impacting stock liquidity and investor confidence.
• Intense Competition: The biopharmaceutical industry, especially in oncology, is highly competitive. Larger companies with greater resources, established products, and more extensive pipelines could develop superior therapies or outcompete Xenetic.
• Reliance on Third Parties: The company heavily relies on third-party contract research organizations (CROs), manufacturers, and consultants for critical aspects of its R&D, clinical trials, and manufacturing. This dependence introduces risks related to quality, timelines, and cost control.
• Intellectual Property Protection: Protecting their proprietary technologies (DNase and PolyXen®) through patents and other means is crucial. Challenges to their intellectual property could severely impact their business.
• Economic and Geopolitical Factors: Broader economic downturns, inflation, supply chain disruptions, and global geopolitical events (e.g., conflicts in Ukraine or the Middle East) could negatively impact their financial condition and ability to raise capital.

Conclusion

Xenetic Biosciences, Inc. presents a high-risk, potentially high-reward investment opportunity. Its future success depends on the successful progression of its DNase technology through clinical trials, the ability to secure significant additional funding, and the effective execution of its strategic review and partnership initiatives. Investors should carefully weigh these substantial risks and the company's current financial position before making any investment decisions.